There was no evidence of any completed late-stage trial with anti-Tau-targeting immunotherapies or antisense oligonucleotides in Alzheimer's disease or with other tauopathies, which demonstrate that anti-Tau therapies are still currently in an early stage of clinical development. The gene discussed is MAPT; the disease is Alzheimer disease.